Defusing SARS-CoV-2: Emergency Brakes in a Vaccine Failure Scenario | ||
| dc.conicet.fuente | individual | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur | |
| dc.conicet.paisOrganizacion | Argentina | |
| dc.conicet.produccionid | 9266269 | |
| dc.contributor.author | Fernandez, Ariel | |
| dc.date.accessioned | 2021-01-05T16:51:57Z | |
| dc.date.available | 2021-01-05T16:51:57Z | |
| dc.date.issued | 2020-12 | |
| dc.date.updated | 2021-01-05T14:26:03Z | |
| dc.description.abstract | Deactivation of primed SARS-CoV-2 prior to cell entry constitutes an emergency brake in COVID-19 infection if vaccine-induced antibodies fail to block recognition of the human angiotensin-converting enzyme 2 (hACE2) receptor. The timing and locus for the therapeutic intervention are dictated by the cell entry mechanism and by the selective advantage of the dominant D614G mutation. | es |
| dc.description.fil | Fil: Fernandez, Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Fernandez, Ariel; Defusing SARS-CoV-2: Emergency Brakes in a Vaccine Failure Scenario; American Chemical Society Inc; ACS Pharmacology and Translational Science; 3; 12-2020; 1425-1426 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 2575-9108 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/121495 | |
| dc.journal.pagination | 1425-1426 | es |
| dc.journal.pais | Estados Unidos | es |
| dc.journal.title | ACS Pharmacology and Translational Science | es |
| dc.journal.volume | 3 | es |
| dc.language.iso | eng | es |
| dc.publisher | American Chemical Society Inc | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://pubs.acs.org/doi/10.1021/acsptsci.0c00152 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1021/acsptsci.0c00152 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | SARS-CoV-2 | es |
| dc.subject | COVID-19 | es |
| dc.subject | antibody | es |
| dc.subject | virus transmissibility | es |
| dc.subject.classification | Biotecnología relacionada con la Salud | es |
| dc.subject.classification | Biotecnología de la Salud | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Defusing SARS-CoV-2: Emergency Brakes in a Vaccine Failure Scenario | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.d869200e-4e74-45bb-aed4-102e2066524c_A.pdf
- Tamaño:
- 1.31 MB
- Formato:
- Adobe Portable Document Format